Goldencross Pharma Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
- Paid Up Capital ₹ 0.46 M
- Company Age 25 Year, 10 Days
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 91.50 Cr
- Revenue Growth 0.89%
- Profit Growth -6.56%
- Ebitda -22.83%
- Net Worth 6.97%
- Total Assets 5.00%
About Goldencross Pharma
Goldencross Pharma Limited (GPL) is a leading Public Limited Indian Non-Government Company incorporated in India on 21 January 2000 and has a history of 25 years. Its registered office is in Thane, Maharashtra, India.
The Corporate was formerly known as Goldencross Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 0.46 M.
The company has closed loans amounting to ₹91.50 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Goldencross Pharma Limited India are Chirag Hotchandani as COMPANY SECRETARY and Pantha Kundu as Cfo. Dinesh Jain, Rajendra Chopra, Anisha Udeshi, and One other member serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24239MH2000PLC123766
- Company No.
123766
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
21 Jan 2000
- Date of AGM
22 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Goldencross Pharma?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ujjwal Shendre  | Managing Director | 24-May-2023 | Current |
| Chirag Hotchandani | Company Secretary | 02-Feb-2022 | Current |
| Pantha Kundu | CFO | 25-Aug-2023 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Dinesh Jain | Director | 14-Nov-2019 | Current |
| Anisha Udeshi | Director | 08-Jun-2020 | Current |
| Rajendra Chopra | Director | 03-Jan-2019 | Current |
Financial Performance of Goldencross Pharma.
Goldencross Pharma Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 0.89% increase. The company also saw a slight decrease in profitability, with a 6.56% decrease in profit. The company's net worth moved up by a moderate rise of 6.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Goldencross Pharma?
In 2021, Goldencross Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Medispray Laboratories Private LimitedDinesh Jain and Anisha Udeshi are mutual person
Meditab Specialities LimitedDinesh Jain, Rajendra Chopra and 1 more are mutual person
- Cipla Pharmaceuticals Limited
Dinesh Jain, Rajendra Chopra and 1 more are mutual person
- Cipla Digital Health Limited
Dinesh Jain, Rajendra Chopra and 1 more are mutual person
Cipla Pharma And Life Sciences LimitedRajendra Chopra and Anisha Udeshi are mutual person
Jay Precision Pharmaceuticals Private LimitedDinesh Jain is a mutual person
Charges (Loans)
₹0
₹91.50 Cr
Charges Breakdown by Lending Institutions
- The Hongkong And Shanghai Banking Corporation Limited : 90.00 Cr
- Credit Lyonnias : 1.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 03 Feb 2009 | The Hongkong And Shanghai Banking Corporation Limited | ₹90.00 Cr | Satisfied |
| 18 Mar 2002 | Credit Lyonnias | ₹7.50 M | Satisfied |
| 08 Mar 2002 | Credit Lyonnias | ₹7.50 M | Satisfied |
How Many Employees Work at Goldencross Pharma?
Goldencross Pharma has a workforce of 322 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Goldencross Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Goldencross Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
